>>661
ããã¯ããããŸãã§ããïœïœ
ã©ã®çšåºŠã®ç«åŠèª¿æ»ãç¥ããŸããããåºæ¬ä»ã®ä¿å¥æã¯ç©æ¥µçã«æ¿åæ¥è§Šè
ãè¿œã£ãŠ
æ€æ»ããŠãªãã§ããããä»çºè¡šã®éœæ§è
ã®æ°åã®å€ãã¯ãçç¶ã®ãã£ã人ãçºç±å€æ¥çãéããŠ
éœæ§ãšå€æãããæ°åã§ãåå±
家æçšåºŠã¯è¿œã£ãŠããŠããã以äžã¯è¿œè·¡ããŠãŸããã
ããã©ãããåãè»å
ã§æ°æéäžç·ã§ãæããã«æ¿åæ¥è§Šè
ãªã®ã«ãä¿å¥æã«äŒããŠã
ãããã¯æ¿åæ¥è§Šã«ã¯ãªããŸãããäœãçç¶ããã£ããé£çµ¡ãã ãããããšã®å¯Ÿå¿ã§æç¶ãšããããšã
ä»ã®ä¿å¥æã¯ç¡çç¶è
ã«å¯ŸããŠã¯æ€æ»ã©ããããæ¿åæ¥è§Šè
ãšãèªãããããªãã§ããã
ïŒèŠã¯æ¥åãéå€ã«ãªããããŠç Žç¶»ããŠããïŒ
ïŒä»¥äžå¥æ 補è¬ïŒšïŒ°ããæç²ïŒ
æ¬ç 究ã¯SARS-CoV-2ææè
ã®ãã¡ç¡çç¶ã®äººãå ããå²åãããã«å€ãããæ¹ããŠæã
ã«ç¥ãããŠãããã
PCRæ€æ»ã«éã£ãŠèšãã°ãæ€æ»éœæ§ãšãªã£ãæç¹ã§ç¡çç¶ã®äººãäžå€®å€ã§42.5%ã«éãããšã®ããšã§ããã
ããã¯ãæ€æ»ãç¹ã«æ£è
ã®æ¥è§Šè
ã«å¯Ÿããæ€æ»ãã©ã®çšåºŠç©æ¥µçã«å®æœããŠããããã«ãã£ãŠç°ãªãæ°å€ã§ãã
å®éãç 究éã§ã30%ïœ80%ãšå€§ããªã°ãã€ããããã
ã€ãŸãç©æ¥µçã«æ€æ»ããã°ããã»ã©ãç¡çç¶ã®éœæ§è
ãå¢ããŠãããšããäºã
ãããç¡çç¶éœæ§è
ã®ïŒå²ä»¥äžã®äººãé°æ§ã«ãªããŸã§ãã£ãšç¡çç¶ã
>>645ã®è©±ãååèãããããšããäºã§ãããïŒïŒïŒïŒåã¯ç¡ããšæããŸããïŒ